# 肽基脯氨酰顺反异构酶Pin1在阿尔茨海默病发生发展中的作用

侯　海2）王敬章 1)\*\*李雪梅 3)(河北工程大学附属医院，医学院，医学检验重点实验室，邯郸056002；2)西北工业大学生命学院，空间生物实验模拟技术重点实验室，西安710072;3)中国科学院生物物理研究所，生物大分子国家重点实验室，北京100101)

摘要Pinl是目前发现的人体内唯一识别蛋白质中 pSer/pThr-Pro 的顺反异构酶，与阿尔茨海默病(Alzheimer's disease，AD)的发生存在重要联系．Pin1调控AD相关分子的结构和功能，抑制神经纤维缠结、老年斑、脑血管淀粉样沉积等AD病理学特征，促进神经前体细胞分化成神经元，在一定程度上起到了阻止AD发生和发展的作用．同时，人体内Pin1功能紊乱可能是AD 发生机制之一，尽管如此，Pinl能否成为预防和治疗AD的靶蛋白还有待临床验证．鉴于目前针对脑内单分子的AD 药物疗效较差，联合Pin1与相关分子的“多靶点药物组合”可能是一种未来AD 防治的研究策略.

关键词Pin1，阿尔茨海默病，神经纤维缠结，老年斑，脑血管淀粉样沉积 学科分类号 $\phantom { - } Q 5 5 8 \substack { + . 2 }$ ，Q71 DOI:10.16476/j.pibb.2015.0057

阿尔茨海默病(Alzheimer'sdisease，AD)是引起记忆和认知功能障碍的一种常见神经退行性疾病，主要病理学特征为脑细胞内神经纤维缠结(neurofibrillarytangles，NFTs)和脑细胞外老年斑(senile plaques，SPs)等[1-3]．AD 发病率随年龄增长不断上升，造成沉重的经济负担[4-5]．在中国人口老龄化的背景下，探索AD发病机制并促进AD 早期防治研究具有重要意义．本文总结了近年来发现的肽基脯氨酰顺反异构酶(peptidyl-prolylcis/transisomerase，PPIase)Pin1在AD发生发展中的作用，并简要评述基于Pin1进行AD防治工作的发展趋势

# 1Pin1的结构特点和功能简述

蛋白质中Ser/Thr-Pro可逆磷酸化是细胞信号的重要调节机制[6-7．Pin1发现于1996年，是目前发现的唯一特异识别pSer/pThr-Pro 的顺反异构酶[6-7.Pin1含163个氨基酸残基，分子质量为 $1 8 ~ \mathrm { k u }$ ，含WW和PPIase两个结构域[8-9]．在Pin1催化反应时，WW结构域特异结合底物的pSer/pThr-Pro,PPIase结构域催化其发生顺反构型转变．Pin1的顺式异构作用调控数十种蛋白质的结构和功能，进而调节一系列下游信号通路，影响多种疾病的发生，例如 AD、癌症、原发性高血压等[7,10-12]．Pin1活性升高可能诱发前列腺癌、乳腺癌、肺癌等[13-16,其活性降低可能导致AD、原发性高血压等[10,12,17].随着研究的深入，Pin1在AD发生发展中的作用不断被揭示出来，对AD防治研究具有一定参考价值.

# 2Pin1对AD发生机制的调控作用

图1简述了Pin1在AD发生发展过程中的主要调控作用．首先，NFTs和SPs分别由Tau蛋白和 $\beta$ 淀粉样蛋白（ $\mathrm { \Delta } \cdot \mathrm { \Delta } \mathrm { \ddot { \beta } }$ -amyloid，Aβ)沉积而成，Pinl促进Tau去磷酸化而阻止其形成NFTs，Pin1减少

Aβ 生成而抑制 $\mathrm { S P s ^ { [ 6 , 1 } }$ 2．其次，脑淀粉样血管病(cerebral amyloid angiopathy，CAA)是AD 的又一特征，Aβ是脑血管淀粉样沉积的主要成分，Pin1阻止 $\mathbf { A } { \boldsymbol { \beta } }$ 在脑血管壁沉积，避免CAA发生[10,18-19]．另外，Pin1通过调控 $\beta$ -catenin和p53等分子，影响神经前体细胞(neural progenitor cells，NPCs)分化和神经元的生长与凋亡.

![](images/a4bdbd9432d7bd261ee12c8ef99d2d1c85cd9f61ac85142d70dd1071ce972ae1.jpg)  
Fig.1The primary roles of Pin1 in regulating the mainpathological characteristics of Alzheimer's disease图1Pin1对阿尔茨海默病主要病理学特征的主要调控作用

# 2.1Pin1抑制神经纤维缠结的形成

如图2所示，Tau过度磷酸化和沉积是形成NFTs 的主要原因[8,20-22]．哈弗大学卢坤平教授最早发现Pin1阻止Tau沉积[23]，随后证实Pin1调控Tau的作用位点主要是Thr231-Pro.Tau的pThr231-Pro具有顺式和反式两种空间构型，Nakamura等首次制备了顺反构型特异性的免疫抗体，并且证实含反式pThr231-Pro 的Tau具有正常生物学功能，而含顺式pThr231-Pro的Tau无微管结合能力并且易沉积[8,20,24-25]．然而，Pin1催化Tau的顺式pThr231-Pro转变为反式构型后，就可以被蛋白磷酸酶 2A(protein phosphatase 2A，PP2A)催化去磷酸化，从而避免沉积和形成 NFTs[7-8,24,26]．如果Pin1活性降低，顺式Tau不能被有效地转变为反式构型，则会加速Tau沉积和NFTs形成[20,26-28].沉积和错误折叠的Tau还可像肮蛋白一样，在神经元之间扩散，逐步引起神经功能障碍[29-30]．此外，Pin1还能促进Tau的Ser202、 $\mathrm { T h r } 2 0 5$ 、Ser235和$\mathrm { { S e r 4 0 4 } }$ 等位点去磷酸化，也有助于防止NFTs形成

![](images/339693f6b953f759794ab227b27ddbc9b625fb5d7165d6f05fc191f91f678385.jpg)  
Fig.2Pinl prevents the formation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in Alzheimer'sdisease 图2Pin1阻止阿尔茨海默病中神经纤维 缠结和老年斑的形成

与此同时，糖原合成酶激酶 $3 \beta$ (glycogensynthase kinase 3beta， $\mathrm { G S K } 3 \beta$ )可催化Tau的多个位点(包括 $\mathrm { T h r } 2 3 1$ )发生磷酸化，推动Tau沉积进程[28,32]．Pin1可以结合在 $\mathrm { G S K } 3 \beta$ 的 $\mathrm { p T h r } 3 3 0 – \mathrm { P r o }$ 而抑制 $\mathrm { G S K } 3 \beta$ 活性；若Pin1活性降低， $\mathrm { G S K } 3 \beta$ 活性就会增强并造成 Tau 沉积加重[33-34]．因此，Pin1既能阻止Tau被GSK3β磷酸化，也能促进已经磷酸化的Tau发生去磷酸化，阻止Tau沉积和NTFs形成.

# 2.2Pin1抑制老年斑的形成

TakafumiUchida和卢坤平研究团队最早发现Pin1 抑制Aβ 生成和沉积，见图2[35-36]．Aβ 是淀粉样蛋白前体(amyloid precursor protein，APP)裂解产生的不溶性多肽[37-38]。 $\mathrm { G S K } 3 \beta$ 催化APP 的 Thr668发生磷酸化，促进APP裂解生成 $\mathsf { A } \mathsf { \beta }$ ；Pin1 抑制$\mathrm { G S K } 3 \beta$ 活性可以减少Aβ生成[33]．Pin1还能结合APP的 $\mathrm { p T h r } 6 6 8 – \mathrm { P r o }$ ，调控APP结构，使APP按照不产生Aβ 的方式降解[35,39]．若将 $\mathrm { G S K } 3 \beta$ 的$\mathrm { T h r } 3 3 0$ 或APP的 $\mathrm { T h r } 6 6 8$ 定点突变后，Pin1抑制Aβ 生成的作用均无法实现33]．因此，Pin1既能阻止APP被 $\mathrm { G S K } 3 \beta$ 磷酸化，也能促使已磷酸化的APP沿着不产生 $\mathbf { A } { \boldsymbol { \beta } }$ 的方式降解，抑制SPs形成.

# 2.3Pin1阻止脑血管淀粉样沉积的产生

一氧化氮(nitric oxide，NO)能促进血管舒张,增强血管动力，增加血液灌注量，防止血管功能紊乱[10.40]．我们曾阐述 Pin1、内皮型一氧化氮合成酶(endothelial nitric oxide synthase，eNOS)和 Aβ 组成一条反馈调控信号通路，其中Pin1和eNOS协同地阻止Aβ 在脑血管中沉积[10,40-4I]．如图3所示，Pin1调控eNOS的pSer116去磷酸化后，会增强eNOS活性和NO生成；Pin1活性降低则引起eNOS过度磷酸化、活性丧失、NO合成量减少等[42-43]．结合上文所述，Pin1 既可以抑制Aβ 生成,也可以增强NO生成和促进脑血管舒张动力，从而阻止 $\mathbf { A } { \boldsymbol { \beta } }$ 在脑血管内壁沉积[1044]．另外，受Pin1 调控的eNOS可以抑制APP表达量，减少生成 $\mathbf { A } { \boldsymbol { \beta } }$ 的原料，也有助于减少 Aβ 沉积和CAA发生[40].

![](images/22a161424853b7f73019ebe6c62bcdf75996577c86717294c65efc56f18e0366.jpg)  
Fig.3Pinl prevents cerebral amyloid angiopathy (CAA）in Alzheimer's disease   
图3Pin1阻止阿尔茨海默病中脑血管淀粉样沉积

胞周期阻滞[s0-51l．如图4所示，Pin1 调控p53-p21信号通路与神经元调亡有关．早期研究认为，Pin1结合p53的 pSer33、pThr81和 pSer315 等位点，增强p53 稳定性及其对p21的转录活性[52-54]．近来研究发现：Pin1活性较高时，倾向于增强p53的下游信号通路；而Pin1活性较低时，则易引起p53泛素化修饰和降解[55]．另外，Pin1还可促使p53与细胞凋亡抑制因子iASPP解离，启动细胞凋亡相关基因(如p21)的表达[54,56].

![](images/37ebd30202e4ce946340c591fae2e3b646600256841a730eaa266c9dc68ea778.jpg)  
Fig.4Pinl regulates the neuron apotosis via the p53-p21 signalling pathway 图4Pin1通过 $\mathbf { p 5 3 - p 2 1 }$ 信号通路调控神经元调亡

# 2.4Pin1促进神经前体细胞分化为神经元

连环素蛋白 $\beta$ -catenin具有促进细胞分化和生长的作用， $\beta$ -catenin活性降低可引起神经元不稳定和调亡[8.45-46]．Pin1 可以结合 $\beta$ -catenin 的 pSer246位点，阻止 $\beta$ -catenin被APC-蛋白酶系统降解，从而增强 $\beta$ -catenin的稳定性和活性[8,47]．进一步而言，有研究发现 $\beta$ -catenin促进神经前体细胞分化成神经元，起到维持神经元正常功能的作用，而当Pin1活性降低时， $\beta$ -catenin的上述作用会受到严重阻碍[45-46,48-49].

# 2.5 Pin1调节神经元凋亡

根据细胞周期调控紊乱假说，肿瘤抑制因子p53可以激活下游基因p21，p21可以引起G1/S细

p53-p21信号通路引发的神经元调亡对AD的意义尚未阐明．一方面，该信号通路过度激活可能加重AD病理．另一方面，由于p53通常在细胞受到损伤时才会显著激活[52-53]，那么如图4所示，当神经元受到损伤时，若Pin1 激活p53-p21信号通路则会促使受损神经元凋亡；否则，受损神经元还可能引起周围正常神经元发生功能障碍[29].

# 3人体内影响Pin1功能的因素及其与 AD发生机制的联系

鉴于Pin1对AD病理学特征的调控作用，人体内Pin1活性降低或丧失可能加速AD的发生和发展．图5列举了人体内影响Pin1功能的一些因素.

![](images/73ed5314c51bdb6cf0305074ca77343581a0c26bd7ff8f367612ea02c6edc65e.jpg)  
Fig.5The factors that inhibit the function of Pin1 in vivo,potentially contributing to the development of Alzheimer'sdisease 图5人体内抑制Pin1活性并可能导致 阿尔茨海默病的因素

# 3.1PIN1基因启动子区多态性

PIN1基因(编码Pin1蛋白)启动子区多态性位点，如 $- 8 4 2 \mathrm { G } \mathrm { > C }$ 和 $- 5 1 8 5 \mathrm { G } \mathrm { > C }$ ，影响PIN1基因转录效率及Pin1蛋白表达量，与AD发病率呈现一定相关性[14,57-59]．与-842G 相比， $- 8 4 2 \mathrm { C }$ 可降低体内 PIN1基因转录效率和Pin1蛋白质含量[14,58]；与-5185G 相比， $- 5 1 8 5 \mathrm { C }$ 会引起体内Pin1蛋白含量上调约2倍[59]．因此，携带-842C或 $- 5 1 8 5 \mathrm { G }$ 等位基因的人群Pin1活性较低，他们分别比 $- 8 4 2 \mathrm { G }$ 或-5185C 等位基因携带者(Pin1活性较高)罹患 AD的风险更高[58-59].

# 3.2转录调控因子

PIN1基因转录效率受到多种转录因子的调控．一方面，对PIN1基因转录起正调控作用的有E2F[60-61]、Notch1[62]、IGF-1[63]等，它们能增强PIN1基因的转录效率，提高体内Pin1蛋白的含量和活性．另一方面，AP4、p53 等可以结合PIN1基因启动子区的功能响应元件，负调控Pin1的基因转录并抑制Pin1 活性[59,64]．这些转录因子与 AD 发生和发展的联系还有待进一步研究.

# 3.3 翻译后修饰

Pin1的一些氨基酸残基可发生翻译后修饰，影响其结构和功能[65-67．蛋白激酶PKA、PKC等可以催化Pin1的Serl6(位于WW 结构域)发生磷酸化，降低Pin1与底物结合的特异性，使Pin1丧失对Tau 的调控作用[26,6．蛋白激酶DAPK1可催化

Pin1的Ser71(位于PPIase 结构域)发生磷酸化，显著抑制Pin1的催化活性[68-69]．在AD 病人的神经组织中还发现Pin1存在氧化修饰，氧化修饰抑制Pin1对底物的催化活性，并影响AD发展进程[70-72].此外，Pin1蛋白翻译后错误折叠引起的沉积也被认为是AD的一种病理学特征[73].

# 3.4 病原性发热

当人体受到外源微生物侵袭时，通常会发生持续发热，长时间发热可引起神经组织发生Tau聚合和 Aβ沉积等，这与Pin1活性丧失所引起的 AD病理学特征类似[74-7．我们利用多种生物化学技术分析了温度升高对Pin1结构和功能的影响，并且发现：Pin1是一种温度敏感型的蛋白质，较高温度可破坏Pin1的二级结构和三级结构，并导致Pin1 活性丧失[7-78]．这些结果对“病原性发热增加AD风险”提供了一种理论解释[].

# 3.5 细胞微环境酸化

随着年龄增长，体内代谢过程异常和代谢产物堆积可以造成细胞微环境酸化，与Aβ沉积和神经元坏死有关[79-80]．早期研究发现酸性pH会显著抑制Pin1活性，最近我们证实酸性pH可以导致Pin1结构中色氨酸微环境改变、二级结构和三级结构破坏等，为酸性pH抑制Pin1 活性提供了结构学证据，这些原因会在一定程度上增强AD发病风险[8I].

# 3.6 金属离子

铝、铜、铁等金属离子代谢紊乱在AD发病早期起着促进作用[82-85]．细胞内铝离子含量与Tau 沉积及NFTs形成显著相关[84,8，铝离子还影响APP降解、Aβ生成和 SPs的形成[87-88]．我们利用定点突变技术构建了Pin1的多个突变体分子，通过分析发现：铝离子特异结合在Pin1的WW结构域，阻碍Pin1与底物的相互作用，并抑制Pin1活性，支持了“高浓度铝离子可能诱发AD”的观点[89].

# 3.7 小分子化合物

由于Pin1在肿瘤发生和转移过程中起促进作用，一些抑制Pin1活性的小分子化合物有可能成为抗癌药物[16,90-91]．例如，表没食子儿茶素(epigallocatechin gallate，EGCG)[92]和紫花前胡素(decursin)[5]等都可抑制Pin1活性，起到一定抗肿瘤效应．那么，当这些物质用于癌症防治时，需要密切关注它们对于神经系统的毒副作用，以及是否会导致AD等疾病．体内脂类物质被氧化的产物4-羟基壬烯酸(4-hydroxynonenal，HNE)可以结合Pin1活性中心的His157和Cys113，抑制Pin1的活性，可能也与AD发生有关[93].

# 4结语和展望

本文简要总结了近几年关于Pin1阻止AD发病的新进展．现在仍缺少有效的AD预防和治疗方法，而且一旦出现AD临床症状则疾病进程难以逆转，因此必须重视AD发病机制和早期干预的研究[30,38,94]．针对AD 病理学特征的复杂性，已有多种关于AD发病机理的理论或假说，包括Aβ沉积、基因调控异常、自由基损伤、钙离子通道受损、胆碱能系统损害、金属离子代谢失衡、基应激等，但都不能完全解释所有的AD病理学特征[21-22,3,82,95]，那么推测 Pin1异常可能也只是AD的重要发病机制之一.

自Pin1被发现以来，它与AD发生和发展的联系备受关注．至今SCI数据库收录Pin1与AD之间联系的论文约160多篇(近3年有50多篇，增长超过 $30 \%$ )，这些研究主要在美国、意大利、法国等，中国的相关研究正在逐年增加．目前相关研究主要集中在细胞和动物实验方面，尚无基于Pin1进行AD治疗的临床研究．不过有研究认为，基于Pin1的蛋白质工程药物或提高神经元中Pin1表达量可能有效治疗 $\mathrm { A D } ^ { [ 6 , 8 , 9 6 ] }$ ．但是，由于AD发病机制呈现“多因异质性”，针对脑内单基因、单分子的AD药物在临床实验中疗效较差(尽管在细胞及动物实验水平有一定作用)[30,38,82.95]，因此基于Pin1进行AD的治疗能否达到较好的临床效果，还有待将来进一步临床实践检验.

尽管如此，基于Pin1进行AD预防和治疗仍是重要的探索方向，只是在未来研究中，需要正确认识Pin1异常与其他AD发病机制的联系，也要正确看待Pin1与其他相关分子在AD发病过程中的协同作用．进一步而言，Pin1在AD中的作用主要归结于它对多条可逆磷酸化信号通路的调控，因为Pin1催化的pSer/pThr-Pro 顺反异构是联系磷酸化和去磷酸化的重要环节；在这些信号通路中，处于 Pin1上游的有催化底物发生磷酸化的 $\mathrm { G S K } 3 \beta$ 、MAPK、CDK等磷酸激酶，而处于Pin1下游的还有催化底物去磷酸化的PP2A等磷酸酯酶，理论上这些分子出现异常都可能导致信号通路阻断并引起相关疾病[68]．因此，参照已有资料，在未来AD 治疗研究中，联合Pin1和其他分子进行“多靶点药物组合”可能是一个研究思路[38,97]．此外，由于

Pin1调控的细胞信号通路具有极高的多样性[67,12,16,Pin1在AD发生和发展中的作用可能远不止上述内容，更加深入的机制还有待进一步探索.

# 参考文献

[1] 李金凤,谢笛,何平平,等．NLRP3 炎性体与代谢性疾病的研 究进展.生物化学与生物物理进展,2014,41(5):425-434 Li JF,Xie D,He PP,et al.Prog Biochem Biophys,2014,41(5): 425-434   
[2] 李兴宇,高灿.突触上与突触外的 NMDA受体及其与阿尔茨 海默病关系的研究进展.生物化学与生物物理进展,2014,41(9): 823-829 Li X Y,Gao C.Prog Biochem Biophys,2014, 41(9): 823-829   
[3] 刘玲玲,盛柏杨,龚错,等．淀粉样肽 Aβ 导致线粒体功能紊 乱的体内和体外研究.生物化学与生物物理进展,2010,37(2): 154-160 Liu LL, Sheng B Y,Gong K,et al. Prog Biochem Biophys,2010, 37(2): 154-160   
[4]Gilbert B J.The role of amyloid beta in the pathogenesis of Alzheimer's disease.JClin Pathol,2013,66(5):362-366   
[5] Dong S, Duan Y,Hu Y,et al. Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener,2012,1(1):18   
[6]Driver JA, Zhou X Z,Lu K P. Regulation of protein conformation byPinl offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease.Discov Med,2014,17(92): 93-99   
[7]Liou YC, Zhou X Z,Lu KP.Prolyl isomerase Pinl asa molecular switch to determine the fate of phosphoproteins.Trends Biochem Sci,2011,36(10): 501-514   
[8]Lu K P.Pinning down cell signaling，cancer and Alzheimer's disease.Trends Biochem Sci,2004,29(4):200-209   
[9]Ranganathan R,Lu K P,Hunter T,et al. Structural and functional analysis of the mitotic rotamase Pinl suggests substrate recognition is phosphorylation dependent.Cell,1997,89(6): 875-886   
[10] Wang JZ, Zhu WD,Xu ZX,et al.Pinl,endothelial nitric oxide synthase，and amyloid-beta form a feedback signaling loop involved in the pathogenesis of Alzheimer's disease,hypertension, and cerebral amyloid angiopathy. Med Hypotheses,2014,82(2): 145-150   
[11] Wang JZ, Zhang YH, Sun X W,et al.Focusing on the structure and the function of Pinl: new insights into the opposite effects of fever on cancers and Alzheimer's disease.Med Hypotheses,2013, 81(2): 282-284   
[12] Lee TH, Pastorino L,Lu K P.Peptidyl-prolyl cis-trans isomerase Pinl in ageing,cancer and Alzheimer disease.Expert Rev Mol Med,2011,13(0): e21   
[13] Lee K H,Lin FC,Hsu TI,et al. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim Biophys Acta,2014,1843(9):2055-2066   
[14] Lu J, Yang L, Zhao H,et al. The polymorphism and haplotypes of and eastern Chinese populations.Hum Mutat，20l1，32 (11): 1299-1308   
[15] Kim J-H,Jung JH, Kim S-H,et al.Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pinl activity and enhancement of the Pinl/p53 assciation. Phytother Res,2014,28(2): 238-244   
[16] Wang JZ,Liu B G, Zhang Y. Pinl-based diagnostic and therapeutic strategies for breast cancer.Pharmacol Res,2015,93C(O): 28-35   
[17] Wang JZ,Li SR,Li Y L,et al.Could Pinl help us conquer essential hypertension atan earlierstage?A promising early-diagnostic biomarker and its therapeutic implications for the disease.Med Hypotheses,2013,81(5): 931-935   
[18] Biffi A, Shulman JM, Jagiella JM,et al.Genetic variation at CR1 increases risk of cerebral amyloid angiopathy.Neurology,2012, 78(5): 334-341   
[19]Grinberg L T，Korczyn A D，Heinsen H.Cerebral amyloid angiopathy impact on endothelium. Exp Gerontol, 2012,47(11): 838-842   
[20] Wang J Z， Zhang Y. Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease.JNeurol Sci,2015,348(1-2): 253-255   
[21]孙丽文,唐孝威,胡应和.淀粉样肽在阿尔茨海默症发病机制中 的分子机制.生物化学与生物物理进展,2007,34(1):18-24 Sun L W,Tang SW,Hu YH. Prog Biochem Biophys,2007,34(1): 18-24   
[22]朱笠,刘江红,吴瑛.转录后基因调控异常与老年性痴呆.生 物化学与生物物理进展,2012,39(8):703-708 Zhu L,Liu JH,Wu Y. Prog Biochem Biophys,2012,39 (8): 703-708   
[23] LuPJ, WulfG, Zhou X Z,et al. The prolyl isomerase Pinl restores the function of Alzheimer-associated phosphorylated tau protein. Nature,1999,399(6738): 784-788   
[24] Nakamura K,Greenwood A,BinderL,et al.Proline isomer-specific antibodies reveal the early pathogenic tau conformationin Alzheimer's disease.Cell,2012,149(1): 232-244   
[25] Nakamura K, Zhou X Z, Lu K P. Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies.Prion, 2013, 7(2): 117-120   
[26] Bulbareli A,Lonati E,Cazzaniga E,et al.Pinl affects Tau phosphorylation in response to A beta oligomers．Mol Cell Neurosci,2009,42(1): 75-80   
[27] Martin L, Latypova X,Terro F.Post-translational modifications of tau protein: implications for Alzheimer's disease.Neurochem Int, 2011,58(4): 458-471   
[28] Lin Y T,Cheng JT,LiangL C,et al．The binding and phosphorylation ofThr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3 beta.J Neurochem,2007,103(2): 802-813   
[29] Wu JW,Herman M,Liu L,et al. Small misfolded tau species are internalizedviabulk endocytosisandanterogradelyand retrogradely transported in neurons.J Biol Chem,2013,288(3): 1856-1870   
[30]崔德华,田小生,王贺成,等.脑衰老与阿尔茨海默病症状出现前 阶段.生物化学与生物物理进展,2012,39(8):741-746 Chui D H, Tian X S, Wang HC,et al.Prog Biochem Biophys, 2012,39(8): 741-746   
[31] Kimura T,Tsutsumi K, Taoka M,et al.Isomerase Pinl stimulates dephosphorylation of tau protein at cyclin-dependent kinase(Cdk5)- dependent Alzheimer phosphorylation sites.The Journal of Biological Chemistry,2013,288(11): 7968-7977   
[32] Berg S,Bergh M,Hellberg S,et al.Discovery of novel potent and highly selective glycogen synthase kinase-3 beta (GSK3 beta) inhibitorsforAlzheimer'sDisease:design，synthesis,and characterization of pyrazines.J Med Chem,2012,55(21): 9107- 9119   
[33] Ma S L,Pastorino L,Zhou X Z,et al.Prolyl isomerase Pinl promotes amyloid precursor protein (APP） turnover by inhibiting glycogensynthasekinase-3beta(GSK3beta）activity:novel mechanism for Pinl to protect against Alzheimer disease.J Biol Chem,2012,287(10): 6969-6973   
[34] Xiong Y S,Wang DL,Tan L,et al.Inhibition of glycogen synthase kinase-3reverses tau hyperphosphorylation induced bypinl down-regulation. CNS Neurol Disord Drug Targets,2013,12 (3): 436-443   
[35] Pastorino L,Sun A,Lu P J,et al.The prolyl isomerase Pinl regulates amyloid precursor protein processing and amyloid-beta production. Nature,2006,440(7083): 528-534   
[36] Akiyama H, Shin R W, Uchida C,et al.Pinl promotes production ofAlzheimer's amyloid beta from beta-cleaved amyloid precursor protein. Biochem Biophys Res Commun,2005,336(2): 521-529   
[37] Duan Y,Dong S,Gu F,et al.Advances in the pathogenesis of Alzheimer's disease:focusing on tau-mediated neurodegeneration. Transl Neurodegener,2012,1(1): 24   
[38]华茜,丁海敏,梁迷.靶向淀粉样蛋白的阿尔茨海默病药物 研究进展.生物化学与生物物理进展,2012,39(8):734-740 Hua Q,Ding HM,Liang M. Prog Biochem Biophys,2012,39(8): 734-740   
[39] Tamayev R, Zhou D,D'adamio L. The interactome of the amyloid betaprecursorproteinfamilymembersisshapedby phosphorylation of their intracellular domains.Mol Neurodegener, 2009, 4(1): 28   
[40] Austin S A, Santhanam A V,Katusic Z S. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res,2010,107(12): 1498-1502   
[41]Toda N.Age-related changes in endothelial function and blood flow regulation.Pharmacol Therapeut,2012,133(2):159-176   
[42] Erol A.Pinl as a protector of vascular endothelial homeostasis. Hypertension, 2012,59(2): e14   
[43] ChiassonVL,Munshi N, ChatterjeeP,et al.Pinl deficiencycauses endothelial dysfunction and hypertension.Hypertension,2011, 58(3): 431-438   
[44] Weller R O,Subash M,Preston S D,et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.Brain Pathol,2008, 18(2): 253-266   
[45] He P,Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease.J Neurosci,20o9,29(20): 6545-6557   
[46] Kitazawa M, Cheng D,Tsukamoto M R,et al. Blocking IL-1 signaling rescues cognition,attenuates tau pathology,and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. JImmunol,2011,187(12): 6539-6549   
[47] Ryo A,Nakamura M,Wulf G,et al. Pinl regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.Nat Cell Biol,2001,3(9): 793-801   
[48]Yu X,Malenka R C.beta-catenin is critical for dendritic morphogenesis. Nat Neurosci,2003,6(11): 1169-1177   
[49] Nakamura K,Kosugi I,Lee D Y,et al.Prolyl isomerase Pinl regulates neuronal diferentiation via beta-catenin. Mol Cell Biol, 2012,32(15):2966-2978   
[50] Tan M,Wang S,Song J,et al. Combination of p53(serl5） and p21/p21 (thrl45） in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers.Neurosci Lett，20l2,516 (2): 226-231   
[51] Yang X,Wang W,Qin JJ,et al. JKA97,a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing Gl arrest, apoptosis,and p53-independent up-regulation of p21.Plos One, 2012, 7(4): e34303   
[52] Zheng HW,YouH, Zhou X Z,et al.The prolylisomerase Pinl is a regulator of p53 in genotoxic response.Nature,2002,419(6909): 849-853   
[53] Zacchi P,Gostissa M, Uchida T,et al.The prolyl isomerase Pinl reveals a mechanism to control p53 functions after genotoxic insults. Nature,2002,419(6909): 853-857   
[54] WulfG M,Liou YC,Ryo A,et al.Role of Pinl in the regulation of p53 stability and p21 transactivation,and cell cycle checkpoints in response to DNA damage.JBiol Chem,2002,277(50):47976- 47979   
[55] Jentsch S,Siepe D.Pinl,a novel switch in the ubiquitin pathway. CellCycle,2009,8(23): 3800-3801   
[56] Mantovani F,Tocco F,Girardini J,et al.The prolyl isomerase Pinl orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP.Nat Struct Mol Biol,2007,14(10): 912-920   
[57] You Y,Deng J, Zheng J,et al.Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese population. Mol Biol Rep,2013,40(2): 829-838   
[58] SegatL,Pontillo A,Annoni G,et al.PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging, 2007, 28(1): 69-74   
[59] Ma SL,Tang NL,Tam C W,et al.A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease.Neurobiol Aging,2012,33(4): 804-813   
[60] Lee KY,Lee JW,Nam HJ,et al.PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pinl induction in tamoxifen-resistant breast cancer cells. Mol Cells,2011,32(1): 107-111   
[61] Kim JA,Kim MR,Kim O,et al.Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pinl inhibition.Food Chem Toxicol,2012,50(10): 3625-3634   
[62] Rustighi A,TiberiL,Soldano A,et al.The prolyl-isomerase Pinl is a Notchl target that enhances Notchl activation in cancer.Nat Cell Biol,2009,11(2): 133-142   
[63] You H, Zheng H W,Murray SA,et al.IGF-1 induces Pinl expression in promoting cell cycle S-phase entry. J Cell Biochem, 2002,84(2): 211-216   
[64] Jeong K,Kim S J,Oh Y,et al. p53 negatively regulates Pinl expression under ER stress.Biochem Biophys Res Commun, 2014, 454(4): 518-523   
[65] Smet-Nocca C,Launay H,Wieruszeski JM,et al. Unraveling a phosphorylation event in a folded protein by NMR spectroscopy: phosphorylation of the Pin1 WW domain by PKA.JBiomol Nmr, 2013,   
[66] Lu PJ, Zhou X Z,Liou Y C,et al.Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pinl function. JBiol Chem,2002,277(4): 2381-384   
[67] Ando K, Dourlen P,Sambo A-V,et al. Tau pathology modulates Pinl post-translational modifications and may be relevant as biomarker.Neurobiol Aging,2013,34(3): 757-769   
[68] Kim B M,You MH, Chen C H,et al.Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis,2014,5: e1237   
[69] Lee TH,Chen CH, Suizu F,et al.Death-associated protein kinase 1 phosphorylates Pinl and inhibits its prolyl isomerase activity and cellular function. Mol Cell,2011,42(2): 147-159   
[70] Balastik M,Lim J,Pastorino L,et al.Pinl in Alzheimer's disease: Multiple substrates,one regulatory mechanism? Bba-Mol Basis Dis,2007,1772(4): 422-429   
[71] Takahashi K,Uchida C,Shin R W,et al.Prolyl isomerase,Pinl: new findings of post-translational modifications and physiological substrates in cancer,asthma and Alzheimer's disease. Cell Mol Life Sci,2008,65(3): 359-375   
[72]Sultana R,Boyd-Kimball D，Poon H F，et al．Oxidative modification and down-regulation of Pinl in Alzheimer's disease hippocampus: A redox proteomics analysis.Neurobiol Aging, 2006,27(7): 918-925   
[73] Dakson A,Yokota O,Esiri M,et al.Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau,A and TDP-43 pathology. Acta Neuropathol,2011,121(5): 635-649   
[74] Aydin M,Girgin FI, Kabakus N,et al.Evaluation of effects of experimental exogenous fever, hyperthermia and various drugs on infant rat brain. Nobel Med,2012,8(3): 66-75   
[75] Favero-Filho L A,Borges A A,Grassl C,et al.Hyperthermia induced after recirculation triggers chronic neurodegeneration in the penumbra zone of focal ischemia in the rat brain. Braz JMed Biol Res,2008,41(11): 1029-1036   
[76] Sinigaglia-Coimbra R,Giordani F,Stavale N,et al.Behavioral and morphological study on the Alzheimer-like rat model induced by postischemic hyperthermia.JNeurol Sci,2005,229: 350-351   
[77] Wang J Z,Lin T,Teng T,et al. Spectroscopic studies on the irreversible heat-induced structural transition of Pin1. Spectrochim Acta A,2011,78(1): 142-147   
[78] Wang JZ,Lin T,Zhu G F,et al. Stability of Pinl as revealed by thermal and spectroscopic studies.JMol Struct,2010,975(1-3): 310-316   
[79] Humpel C.Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?Exp Gerontol,2011,46(4):225-232   
[80]Marksteiner J,Humpel C.Beta-amyloid expression,release and extracellular deposition in aged rat brain slices.Mol Psychiatr, 2008,13(10): 939-952   
[81]Wang JZ,XiL,Zhu GF,et al.The acidic pH-induced structural changesinPinlasrevealed byspectral methodologies. Spectrochim Acta A,2012,98(0): 199-206   
[82]赵保路,万莉.金属离子代谢平衡失调与阿尔茨海默病早期发 病机制.生物化学与生物物理进展,2012,39(8):756-763 Zhao B L,Wan L.Prog Biochem Biophys,2012,39(8): 756-763   
[83]Lemire J,Appanna V D.Aluminum toxicity and astrocyte dysfunction: a metabolic link to neurological disorders.J Inorg Biochem,2011,105(11):1513-1517   
[84] House E,Esiri M,Forster G,et al.Aluminium,iron and copper in human brain tissues donated to the medical research council's cognitive function and ageing study.Metallomics,2012,4(1): 56-65   
[85]Frisardi V, Solfrizzi V,Capurso C,et al.Aluminum in the diet and Alzheimer's disease:from current epidemiology to possible disease-modifying treatment.JAlzheimers Dis,2010,20(1):17-30   
[86]Walton JR. Evidence for participation of aluminum in neurofibrillary tangle formation and growth in Alzheimer's disease. JAlzheimers Dis,2010,22(1): 65-72   
[87]Walton J R，Wang M X. APP expression，distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease.JInorg Biochem,2009,103(11):1548-1554   
[88]Yumoto S,Kakimi S,Ohsaki A,et al.Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease.JInorg Biochem,20o9,103(11): 1579-1584   
[89] Wang JZ,Liu J,Lin T,et al.Aluminum(II) interferes with the structure and the activity of the peptidyl-prolyl cis-trans isomerase (Pinl):a new mechanism contributing to the pathogenesis of Alzheimer's disease and cancers?.J Inorg Biochem，2013, 126: 111-117   
[90]Mori T,Hidaka M, Ikuji H,et al.A high-throughput screen for inhibitors of the prolyl isomerase,Pinl,identifies a seaweed polyphenol that reduces adipose cell differentiation.Biosci Biotech Bioch,2014,78(5): 832-838   
[91] Moore JD,Potter A.Pinl inhibitors:Pitfalls,progress and cellular pharmacology.Bioorg Med Chem Lett,2013,23(15): 4283-4291   
[92] Urusova D V,ShimJH,Kim D J,et al.Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev Res (Phila),2011,4(9):1366-1377   
[93]Aluise C D，Rose K,Boiani M，etal.Peptidyl-prolyl cis/trans-isomerase Al (Pinl) is a target for modification by lipid electrophiles.Chem Res Toxicol,2013,26(2):270-279   
[94]贾建平,王芬,袁泉,等.老年性痴呆早期的基因变异研究进 展.生物化学与生物物理进展,2012,39(8):698-702 Jia JP,Wang F,Yuan Q,et al.Prog Biochem Biophys,2012, 39(8): 698-702   
[95]印大中,刘文锋.基应激与衰老机理及阿尔茨海默病早期分子 病因.生物化学与生物物理进展,2012,39(8):747-755 Yin D Z,Liu WF.Prog Biochem Biophys,2012,39(8): 747-755   
[96]Driver JA.Understanding the link between cancer and neurodegeneration.JGeriatr Oncol,2012,3(1): 58-67   
[97]李林,张兰.中药治疗阿尔茨海默病的作用特点.生物化学 与生物物理进展,2012,39(8):816-828 LiL,Zhang L. Prog Biochem Biophys,2012,39(8): 816-828

# The Role of the Peptidyl-Prolyl cis/trans Isomerase Pinl in The Occurrence and Development of Alzheimer's Disease\*

HOU Hai², WANG Jing-Zhangl)\*\*, LI Xue-Mei3)

（ $^ { 1 ) }$ KeyLaboratorcoefedialbesteg; 2KeyLbatoeetelflUi; 3National Laboratoryofomacromolecules,InstituteofBiophsics,ChineseAcademyofSciences,Beijingoo,Cha)

AbstractPinl is theonly known cis-trans isomerase that recognizes pThr/pSer-Pro in proteins,relevant to the pathogenesis of Alzheimer's disease (AD).Pinl regulates the structures and functions of some molecules that are related to AD, inhibits the main AD pathological characteristics such as neurofibrillary tangles (NFTs),senile plaques (SPs),and cerebral amyloid angiopathy (CAA),promotes the diffrentiation of neural progenitor cells (NPCs）to neurons，and to some extent prevents the occurrence and development of AD.Meanwhile,Pinl dysfunction in vivo may be involved in the pathogenesis of AD.Nevertheless, whether Pinl could be a therapeutic target for the prevention and treatment of AD stillneeds to be verified clinically. Considering ofthe poor efficacy of AD medicines that target each single molecule in brain,the "combined multiple-target medicine" focusing on Pinl and other related molecules may be a therapeutic strategy for AD in the future.

Key wordsPin1, Alzheimer's disease, neurofibrillry tangles,senile plaques,cerebral amyloid angiopathy DOI: 10.16476/j.pibb.2015.0057